Immunovia AB (OSTO:IMMNOV)
kr 0.618 -0.01 (-1.59%) Market Cap: 104.88 Mil Enterprise Value: 76.83 Mil PE Ratio: 0 PB Ratio: 2.91 GF Score: 44/100

Q1 2020 Immunovia AB (publ) Earnings Call Transcript

Apr 28, 2020 / 02:30PM GMT
Release Date Price: kr70.54 (+4.22%)
Operator

Hello, and welcome to the Immunovia Q1 Conference Call. My name is Jas, and I'll be your coordinator for today's event. (Operator Instructions) I will now hand you over to your host, Mats Grahn, CEO, to begin today's call. Thank you.

Mats Grahn;publ;CEO
Immunovia AB

()-

Yes. Good afternoon or good morning wherever you are. It is a pleasure to welcome you to this quarter 1 report from Immunovia. And we will, today, after this slide, also go through the agenda, which is the first quarter highlights, of course. It's our response to the ongoing pandemic. We'll talk about the remaining steps to launch of IMMray PanCan-d, our test for early detection of pancreas cancer; touch on the commercial launch preparation activities; the prospective studies; and then there will be some short information about the upcoming AGM; and we'll finish up with questions.

So the first thing is the highlights that we have had in quarter 1. And we -- the most important thing is, of course, that the verification study of IMMray PanCan-d proceeds as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot